Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYSUCC-001: Adjuvant Capecitabine in TNBC
NCT01112826Phase 3Completed
- Sponsor
- Sun Yat-sen University
- Start
- Apr 2010
- Primary completion
- Dec 2019
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of capecitabine in triple-negative breast cancer (TNBC) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Disease-Free Survival at 5 years. Started Apr 2010; status: completed.
02
Drugs
capecitabine
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT01112826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01112826.